Physician profile
Lushell Hayes
NPI 1437740842
$3,570.37
in general payments reported to CMS, 2019-2025
25 companies · $265 in 2025
The $265 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,171 · 2022: $588 · 2023: $458 · 2024: $1,088 · 2025: $265.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,811.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,811.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $449.43 | 2021-2025 | Farxiga |
| Janssen Pharmaceuticals, INC | $411.45 | 2021-2024 | Xarelto |
| Pfizer INC. | $282.59 | 2021-2025 | |
| Actelion Pharmaceuticals US, INC. | $275.55 | 2021-2025 | Uptravi, Opsumit, Opsynvi |
| E.R. Squibb & Sons, L.L.C. | $237.94 | 2023-2024 | Camzyos, Eliquis |
| United Therapeutics Corporation | $225.69 | 2021 | |
| Glaxosmithkline, LLC. | $208.77 | 2021 | |
| Novartis Pharmaceuticals Corporation | $170.04 | 2022-2024 | |
| Novo Nordisk INC | $164.02 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $157.57 | 2021 | |
| Amgen INC. | $146.87 | 2023-2025 | Repatha, Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $129.96 | 2021-2024 | Lifevest |
| Merck Sharp & Dohme LLC | $119.16 | 2022-2025 | Verquvo |
| Paratek Pharmaceuticals, INC. | $117.73 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $85.00 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $71.42 | 2025 | |
| Genzyme Corporation | $59.52 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $56.00 | 2021 | |
| Amarin Pharma, INC. | $48.21 | 2021-2022 | |
| Kiniksa Pharmaceuticals International, Plc | $39.34 | 2024 | Arcalyst |
| Takeda Pharmaceuticals U.S.A., INC. | $35.56 | 2021 | |
| Kiniksa Pharmaceuticals, LTD. | $30.45 | 2021-2023 | Arcalyst |
| Sanofi-Aventis U.S. LLC | $19.99 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $14.27 | 2021 | |
| Mylan Specialty L.P. | $13.84 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lushell Hayes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.